Design, Synthesis, Characterization, and Cytotoxicity of New Pyrazolylmethylene-2-thioxoimidazolidin-4-one Derivatives Towards Androgen-Sensitive LNCaP Prostate Cancer Cells

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2024 Jul 27

PMID 39062524

Authors

Mohamed A El-Atawy

Rashad Kebeish

Awatif Rashed Z Almotairy

Alaa Z Omar

Affiliations

Soon will be listed here.

Abstract

A new class of pyrazolylmethylene-2-thioxoimidazolidin-4-one derivatives were rationally designed and synthesized with the aim of exploring their potential as treatments for prostate cancer. The synthesized compounds were biologically analyzed for their anticancer effects against ARLNCaP, ARPC-3, and Wi38 cell lines. The observed IC values against ARLNCaP ranged between 10.27 ± 0.14 and 109.72 ± 2.06 µM after 24 h of incubation. Compounds , , and recorded IC values of 05.22 ± 0.12 to 11.75 ± 0.07 µM after 48 h incubation in the presence of 1 nM DHT, with higher selectivity towards ARLNCaP. Moreover, compounds and significantly induced Caspase 3 accumulation, reduced DNA content at the various stages of the cell cycle, and ultimately caused ARLNCaP cell growth arrest, as confirmed by cell apoptosis assays. These findings suggest that these analogues of androgen receptor blockers have promising potential for further investigation as effective treatments for prostate cancer.

References

El-Atawy M, Omar A, L Alazmi M, S Alsubaie M, Hamed E, Ahmed H . Synthesis and characterization of new imine liquid crystals based on terminal perfluoroalkyl group. Heliyon. 2023; 9(4):e14871. PMC: 10070094. DOI: 10.1016/j.heliyon.2023.e14871. View

Luan H, Xu P, Meng Y, Li Z, Bian J . A critical update on the strategies towards modulators targeting androgen receptors. Bioorg Med Chem. 2020; 28(13):115554. DOI: 10.1016/j.bmc.2020.115554. View

Ettridge K, Bowden J, Chambers S, Smith D, Murphy M, Evans S . "Prostate cancer is far more hidden…": Perceptions of stigma, social isolation and help-seeking among men with prostate cancer. Eur J Cancer Care (Engl). 2017; 27(2):e12790. DOI: 10.1111/ecc.12790. View

Zhang M, Liang Y, Li H, Liu M, Wang Y . Design, synthesis, and biological evaluation of hydantoin bridged analogues of combretastatin A-4 as potential anticancer agents. Bioorg Med Chem. 2017; 25(24):6623-6634. DOI: 10.1016/j.bmc.2017.10.045. View

Zuliani V, Carmi C, Rivara M, Fantini M, Lodola A, Vacondio F . 5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. Eur J Med Chem. 2009; 44(9):3471-9. DOI: 10.1016/j.ejmech.2009.01.035. View

Cherneva E, Atanasova M, Buyukliev R, Tomovic K, Smelcerovic Z, Bakalova A . 3'-Methyl-4-thio-1H-tetrahydropyranspiro-5'-hydantoin platinum complex as a novel potent anticancer agent and xanthine oxidase inhibitor. Arch Pharm (Weinheim). 2020; 353(7):e2000039. DOI: 10.1002/ardp.202000039. View

Carter N, Keam S . Degarelix: a review of its use in patients with prostate cancer. Drugs. 2014; 74(6):699-712. DOI: 10.1007/s40265-014-0211-y. View

Msaouel P, Pissimissis N, Halapas A, Koutsilieris M . Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab. 2008; 22(2):341-55. DOI: 10.1016/j.beem.2008.01.011. View

Cao S, Rogers J, Yeo J, Anderson-Steele B, Ashby J, David S . 2'-Fluorinated Hydantoins as Chemical Biology Tools for Base Excision Repair Glycosylases. ACS Chem Biol. 2020; 15(4):915-924. PMC: 7351077. DOI: 10.1021/acschembio.9b00923. View

10.

Millar J . Triptorelin approved for prostate cancer treatment. Am J Health Syst Pharm. 2000; 57(15):1386. DOI: 10.1093/ajhp/57.15.1386. View

11.

Han J, Tweedell R, Kanneganti T . Evaluation of Caspase Activation to Assess Innate Immune Cell Death. J Vis Exp. 2023; (191). PMC: 10202388. DOI: 10.3791/64308. View

12.

El-Atawy M, Alshaye N, Elrubi N, Hamed E, Omar A . Pyrimidines-Based Heterocyclic Compounds: Synthesis, Cytoxicity Evaluation and Molecular Docking. Molecules. 2022; 27(15). PMC: 9370056. DOI: 10.3390/molecules27154912. View

13.

Hwang J, Kim H, Park D, Choi J, Baek S, Kim K . Identification of a series of 1,3,4-trisubstituted pyrazoles as novel hepatitis C virus entry inhibitors. Bioorg Med Chem Lett. 2013; 23(23):6467-73. DOI: 10.1016/j.bmcl.2013.09.039. View

14.

Kumi-Diaka J, Sanderson N, Hall A . The mediating role of caspase-3 protease in the intracellular mechanism of genistein-induced apoptosis in human prostatic carcinoma cell lines, DU145 and LNCaP. Biol Cell. 2001; 92(8-9):595-604. DOI: 10.1016/s0248-4900(00)01109-6. View

15.

van de Loosdrecht A, Beelen R, Ossenkoppele G, Broekhoven M, Langenhuijsen M . A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods. 1994; 174(1-2):311-20. DOI: 10.1016/0022-1759(94)90034-5. View

16.

Yao C, Hsieh T, Song J, Lee J . Design, synthesis and anticancer evaluation of β-carboline-1-one hydantoins. Future Med Chem. 2019; 12(3):183-192. DOI: 10.4155/fmc-2019-0276. View

17.

Kumar S . The apoptotic cysteine protease CPP32. Int J Biochem Cell Biol. 1997; 29(3):393-6. DOI: 10.1016/s1357-2725(96)00146-x. View

18.

Mabjeesh N, Willard M, Frederickson C, Zhong H, Simons J . Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res. 2003; 9(7):2416-25. View

19.

Fontana D, Mari M, Martinelli A, Boccafoschi C, Magno C, Turriziani M . 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. Urol Int. 2003; 70(4):316-20. DOI: 10.1159/000070142. View

20.

Wang Y, Shi T, Fu J, Zhu H . Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination. Eur J Med Chem. 2019; 171:209-220. DOI: 10.1016/j.ejmech.2019.03.026. View